

# Topisches Capsaicin zur Behandlung der Post-Zoster Neuralgie

## Ein Fallbericht

S. Scheike

## Literatur

- [1] Lim, D.Z.J.; Tey, H.L.; Salada, B.M.A.; Oon, J.E.L.; Seah, E.-J.D.; Chandran, N.S.; Pan, J.Y. Herpes Zoster and Post-Herpetic Neuralgia – Diagnosis, Treatment, and Vaccination Strategies. *Pathogens* 2024, 13, 596. <https://doi.org/10.3390/pathogens13070596>
- [2] AWMF S2k-Leitlinie „Diagnostik und Therapie des Zoster und der Postzosterneuralgie“. 2019.
- [3] Jeffrey M. Weinberg. (2007). Herpes zoster: Epidemiology, natural history, and common complications., 57(6-suppl-S), 0–. doi:10.1016/j.jaad.2007.08.046
- [4] Thompson RR, Kong CL, Porco TC, Kim E, Ebert CD, Acharya NR. Herpes Zoster and Postherpetic Neuralgia: Changing Incidence Rates From 1994 to 2018 in the United States. *Clin Infect Dis*. 2021 Nov 2;73(9):e3210–e3217. doi: 10.1093/cid/ciaa1185. PMID: 32829399; PMCID: PMC8563174.
- [5] Meister W, Neiss A, Gross G, Doerr HW, Hobel W, Malin JP, et al. A prognostic score for postherpetic neuralgia in ambulatory patients. *Infection*. 1998;26(6):359–63
- [6] Hadley, G.R.; Gayle, J.A.; Ripoll, J.; Jones, M.R.; Argoff, C.E.; Kaye, R.J.; Kaye, A.D. Post-Herpetic Neuralgia: A Review. *Curr. Pain Headache Rep*. 2016, 20, 17
- [7] Johnson, Robert W; Wasner, Gunnar; Saddier, Patricia; Baron, Ralf. (2007). Postherpetic neuralgia: epidemiology, pathophysiology and management. , 7(11), 1581–1595. doi:10.1586/14737175.7.11.1581
- [9] Erlenwein J, Thoms KM, Brandebusemeyer F, Pfingsten M, Mansur A, Quintel M, et al. Preexisting Chronic Pain Influences the Severity of Acute Herpes Zoster Pain–A Prospective Observational Cohort Study
- [10] Jung, B.F.; Johnson, R.W.; Griffin, D.R.; Dworkin, R.H. Risk factors for postherpetic neuralgia in patients with herpes zoster. *Neurology* 2004, 62, 1545–1551
- [11] Dworkin, R.H.; Johnson, R.W.; Breuer, J.; Gnann, J.W.; Levin, M.J.; Backonja, M.; Betts, R.F.; Gershon, A.A.; Haanpää, M.L.; McKendrick, M.W.; et al. Recommendations for the management of herpes zoster. *Clin. Infect. Dis*. 2007, 44 (Suppl. 1), S1–S26
- [12] Bulilete, O.; Leiva, A.; Rullán, M.; Roca, A.; Llobera, J.; PHN Group. Efficacy of gabapentin for the prevention of postherpetic neuralgia in patients with acute herpes zoster: A double blind, randomized controlled trial. *PLoS ONE* 2019, 14, e0217335.

- [13] Wiffen PJ, Derry S, Bell RF, Rice AS, Tolle TR, Phillips T, et al. Gabapentin for chronic neuropathic pain in adults. *Cochrane Database Syst Rev.* 2017;6:Cd007938.
- [14] Watson, C.P.; Vernich, L.; Chipman, M.; Reed, K. Nortriptyline versus amitriptyline in postherpetic neuralgia: A randomized trial. *Neurology* 1998, 51, 1166–1171
- [15] Pitton Rissardo J, Fornari Caprara AL, Casares M, Skinner HJ, Hamid U. Antiseizure Medication-Induced Alopecia: A Literature Review. *Medicines (Basel)*. 2023 Jun 9;10(6):35. doi: 10.3390/medicines10060035. PMID: 37367730; PMCID: PMC10301592.
- [16] Fujiwake, H., Oka, S.T., Iwai K, S., 1980. Enzymatic formation of capsaicinoid from vanillylamine and iso-type fatty acids by cell-free extracts of *Capsicum annum* var. *annuum* cv. *Karayatsubusa*. *Agric. Biol. Chem.* 44, 5
- [17] Sharma SK, Vij AS, Sharma M. Mechanisms and clinical uses of capsaicin. *Eur J Pharmacol.* 2013 Nov 15;720(1-3):55-62. doi: 10.1016/j.ejphar.2013.10.053. Epub 2013 Nov 5. PMID: 24211679.
- [18] Derry S, Rice AS, Cole P, Tan T, Moore RA. Topical capsaicin (high concentration) for chronic neuropathic pain in adults. *Cochrane Database Syst Rev.* 2017 Jan 13;1(1):CD007393. doi: 10.1002/14651858.CD007393.pub4. PMID: 28085183; PMCID: PMC6464756.
- [19] Deutsche Schmerzgesellschaft e.V., Deutsche Gesellschaft für Geriatrie e.V., UVSD SchmerzLOS e.V. (Hrsg.) (2025): S3-Leitlinie Schmerzmanagement bei Geriatrischen Patient:innen in allen Versorgungssettings (GeriPAIN). Langfassung 1.0, 2025, AWMF- Registernummer 145/005, <https://register.awmf.org/de/leitlinien/detail/145-005>
- [20] Armstrong EP, Malone DC, McCarberg B et al. Cost-effectiveness analysis of a new 8% capsaicin patch compared to existing therapies for postherpetic neuralgia. *Current Medical Research and Opinion* 2011; 27: 939–950. doi:10.1185/03007995.2011.562885
- [21] Samper Bernal D, Pena Vergara I, Vaamonde Torres N et al. Análisis de minimización de costes del tratamiento del dolor neuropático periférico en España con parches cutáneos 179 mg de capsaicina (8%) frente a gabapentinoides. *Revista Española de Economía de la Salud* 2019; 14: 1012–1025
- [22] Thiem H et al. Nutzen und Wirtschaftlichkeit der Topischen Behandlung Peripherer Neuropathischer Schmerzen mit dem Capsaicin-Pflaster Qutenza – ein Literaturüberblick *Gesundheitsökon Qual manag* 2022; 27: 210–219 | © 2022.